With the more extensive technique showing no added value, the health system modified their ELISA reporting recommendations in 2023 to call for the sole use of the low-heparin OD approach.
They exhibit remarkable sensitivity, wide dynamic range and robust performance that compares advantageously with conventional enzyme-linked immunosorbent assay (ELISA). ELISA is the most widely ...